{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05939947",
            "orgStudyIdInfo": {
                "id": "ALE.F02.02"
            },
            "organization": {
                "fullName": "Alentis Therapeutics AG",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis",
            "officialTitle": "A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis",
            "acronym": "FEGATO-01",
            "therapeuticArea": [
                "Gastroenterology"
            ],
            "study": "a-clinical-trial-of-ale-in-patients-with-advanced-liver-fibrosis-and-or-with-mild-cirrhosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-06-21",
            "studyFirstSubmitQcDate": "2023-07-10",
            "studyFirstPostDateStruct": {
                "date": "2023-07-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Alentis Therapeutics AG",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate how a human body processes ALE.F02 (pharmacokinetics profile) in patients with impaired liver function."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Liver Fibrosis",
                "Liver Cirrhosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Thirty-eight patients will receive 3 doses of ALE.F02 or matching placebo, administered once every second week as a continuous intravenous (IV) infusion to a total of 3 doses per patient at the same dose level. The 4 cohorts are enrolled in a staggered sequence and escalated upon review and approval of a Safety Review Committee: Cohort 1 (low dose) (4:2 active:placebo), Cohort 2 (intermediate dose) (8:4), Cohort 3 (intermediate dose) (8:2), Cohort 4 (high dose) (8:2).",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "maskingDescription": "Double-blind",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 38,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ALE.F02",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will receive 3 doses of ALE.F02 administered once every second week as a continuous intravenous (IV) infusion to a total of 3 doses.",
                    "interventionNames": [
                        "Drug: ALE.F02"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Patients will receive 3 doses of matching placebo administered once every second week as a continuous intravenous (IV) infusion to a total of 3 doses.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ALE.F02",
                    "description": "Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.",
                    "armGroupLabels": [
                        "ALE.F02"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pharmacokinetics (PK) profile of ALE.F02 in patients with advanced liver fibrosis and/or with mild cirrhosis using noncompartmental analysis.",
                    "description": "Maximum Serum Concentration \\[Cmax\\]",
                    "timeFrame": "Baseline to Day 14 and Day 29 to Day 72"
                },
                {
                    "measure": "Pharmacokinetics (PK) profile of ALE.F02 in patients with advanced liver fibrosis and/or with mild cirrhosis using noncompartmental analysis.",
                    "description": "Time of Maximum Serum Concentration \\[Tmax\\]",
                    "timeFrame": "Baseline to Day 14 and Day 29 to Day 72"
                },
                {
                    "measure": "Pharmacokinetics (PK) profile of ALE.F02 in patients with advanced liver fibrosis and/or with mild cirrhosis using noncompartmental analysis.",
                    "description": "Area under the serum concentration versus time curve \\[AUC0-tau, AUC0-inf\\]",
                    "timeFrame": "Baseline to Day 14 and Day 29 to Day 72"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of ALE.F02 in patients with advanced liver fibrosis and/or with mild cirrhosis.",
                    "description": "Incidence of Treatment-Emergent Adverse Events assessed by CTCAE v5.0 criteria\n\nIncidence of Serious Adverse Events assessed by CTCAE v5.0 criteria",
                    "timeFrame": "Baseline to Day 72"
                },
                {
                    "measure": "Pharmacodynamic (PD) profile of ALE.F02 in patients with advanced liver fibrosis and/or with mild cirrhosis.",
                    "description": "Relative change (%) of serum levels of PRO-C3 between baseline and the EOT.\n\nRelative change (%) of serum levels of tissue inhibitor of matrix metalloproteinase \\[TIMP1\\] between baseline and the EOT.\n\nRelative change (%) of serum levels of hyaluronic acid between baseline and the EOT.\n\nRelative change (%) of serum levels of procollagen III amino-terminal peptide \\[PIIINP\\] between baseline and the EOT.",
                    "timeFrame": "Baseline to Day 72"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Principal Inclusion Criteria:\n\n* Outpatients between 18 and 80 years\n* Have been diagnosed with advanced liver fibrosis or mild cirrhosis attributable to NASH, ALD, or following a sustained virological response to treatment for hepatitis C\n* Have an ELF Score of at least 9.5 but no more than 13\n* Have stable hepatic impairment, defined as no clinically significant change in disease status, and no previous liver cirrhosis decompensation episodes\n* Body weight within the range of 50.0 kg to 140.0 kg\n* Clinical frailty score \\<6\n\nPrincipal Exclusion Criteria:\n\n* Child-Pugh score \u22657, as determined at screening\n* MELD score \u226512, as determined at screening\n* Estimated glomerular filtration rate \\<60 mL/min per the CKD-EPI creatinine-cystatin C equation\n* Current or history of HCC\n* Be suffering from or have symptoms of an acute or chronic infection\n* Have active hepatitis C infection\n* Other causes of liver disease including, but not limited to, hepatitis B, autoimmune disorders drug-induced hepatotoxicity, Wilson's disease, iron overload, and alpha-1-antitryspin deficiency, based on medical history review.\n* Is a woman of childbearing potential",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Daniela Schmitter, PhD",
                    "role": "CONTACT",
                    "phone": "+41782366290",
                    "email": "daniela.schmitter@alentis.ch"
                },
                {
                    "name": "Markus Meyer, PhD",
                    "role": "CONTACT",
                    "phone": "+41763379886",
                    "email": "markus.meyer@alentis.ch"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Luigi Manenti, MD",
                    "affiliation": "Alentis Therapeutics AG",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "American Research Corporation",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "APEX GmbH",
                    "status": "RECRUITING",
                    "city": "Munich",
                    "zip": "81241",
                    "country": "Germany",
                    "contacts": [
                        {
                            "name": "Gernot Klein, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.13743,
                        "lon": 11.57549
                    }
                },
                {
                    "facility": "ARENSIA Exploratory Medicine S.R.L.",
                    "status": "RECRUITING",
                    "city": "Bucharest",
                    "zip": "011665",
                    "country": "Romania",
                    "contacts": [
                        {
                            "name": "Carmen Georgeta Fierbinteanu-Braticevici, Prof.",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.43225,
                        "lon": 26.10626
                    }
                },
                {
                    "facility": "ARENSIA Exploratory Medicine S.R.L. - Cluj-Napoca",
                    "status": "RECRUITING",
                    "city": "Cluj-Napoca",
                    "zip": "400006",
                    "country": "Romania",
                    "contacts": [
                        {
                            "name": "Adriana Bintintan, Dr.",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.76667,
                        "lon": 23.6
                    }
                },
                {
                    "facility": "Summit Clinical Research",
                    "status": "RECRUITING",
                    "city": "Bratislava",
                    "zip": "851 05",
                    "country": "Slovakia",
                    "contacts": [
                        {
                            "name": "Viera Kupcova, Prof.",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.14816,
                        "lon": 17.10674
                    }
                },
                {
                    "facility": "Summit Clinical Research",
                    "status": "RECRUITING",
                    "city": "Malacky",
                    "zip": "90122",
                    "country": "Slovakia",
                    "contacts": [
                        {
                            "name": "Edita Kadlubiakova, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.43604,
                        "lon": 17.02188
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008103",
                    "term": "Liver Cirrhosis"
                },
                {
                    "id": "D000005355",
                    "term": "Fibrosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8485",
                    "name": "Fibrosis",
                    "asFound": "Fibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11103",
                    "name": "Liver Cirrhosis",
                    "asFound": "Liver Fibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}